RAD-140, also known by its research name Testolone, is a nonsteroidal selective androgen receptor modulator (SARM) that has drawn significant attention in preclinical pharmacology for its selective activity at androgen receptors in muscle and bone tissue. Originally developed as a research tool to study tissue-selective androgen signaling, RAD-140 has become a frequent subject of investigation in strength and muscle science, particularly among researchers examining how androgen receptor modulation might be decoupled from the off-target effects associated with anabolic steroids.
This article reviews what current research indicates about RAD-140 in the context of strength and muscle science, without making therapeutic or performance claims. RAD-140 is not approved by the U.S. Food and Drug Administration (FDA) for any human or veterinary use, and it is intended strictly for laboratory research purposes only. The findings discussed below come from preclinical and early-phase investigational literature, not clinical or consumer guidance.
Overview and Biochemical Characteristics
RAD-140 is classified as a nonsteroidal SARM, structurally distinct from testosterone and other anabolic-androgenic steroids despite sharing a common receptor target. Its non-steroidal backbone is theorized to allow for greater tissue selectivity, meaning it may preferentially engage androgen receptors in skeletal muscle and bone while exhibiting comparatively lower activity in tissues such as the prostate, at least in early preclinical models (Miller et al., 2011).
Unlike testosterone, which is subject to aromatization into estrogenic metabolites, RAD-140’s non-aromatizable structure has made it a useful research model for isolating androgen receptor-specific effects from broader hormonal cascades, a distinction that continues to inform its use in comparative endocrine research.
Mechanisms of Action
Research suggests RAD-140 functions primarily as a high-affinity ligand for the androgen receptor (AR), with preclinical binding studies indicating a comparable or greater binding affinity relative to testosterone in select assay conditions (Miller et al., 2011).
Androgen Receptor Signaling
Investigations indicate that upon receptor binding, RAD-140 is hypothesized to activate downstream transcriptional pathways associated with muscle protein synthesis, similarly to endogenous androgen signaling, though the full transcriptional profile remains an area of ongoing study.
Tissue Selectivity Hypothesis
A central research question surrounding RAD-140 involves its proposed tissue selectivity, the theory that it may activate anabolic pathways in muscle and bone tissue while producing reduced activation in androgen-sensitive tissues elsewhere. This hypothesis has been examined in animal models but has not been confirmed in controlled human trials.
Neuroprotective Signaling Research
Some preclinical work has also explored RAD-140 in models of neurodegeneration, hypothesizing a possible role for androgen receptor activation in neuronal survival pathways, an area of research entirely separate from musculoskeletal applications (Jayaraman et al., 2014).
Research Applications and Domains
Musculoskeletal and Strength Science Research
The majority of RAD-140 literature relevant to strength and muscle science comes from rodent models evaluating lean muscle mass and levator ani muscle weight, a standard proxy tissue used in SARM research to assess anabolic activity relative to androgenic activity (Miller et al., 2011). Researchers have used this model to compare RAD-140’s tissue-selectivity profile against testosterone propionate under controlled laboratory conditions.
Endocrine Research
RAD-140 has also served as a research tool in studies examining hypothalamic-pituitary-gonadal (HPG) axis feedback, since androgen receptor agonists are known to influence endogenous hormone signaling loops. This research has contributed to a broader understanding of how selective androgen receptor modulators interact with the endocrine system as a whole.
Oncology-Adjacent Research
Because androgen receptor signaling plays a role in certain hormone-sensitive cancers, RAD-140 has appeared in early oncology-adjacent research exploring androgen receptor-positive breast cancer models, an application entirely distinct from strength or muscle research but relevant to understanding the compound’s receptor pharmacology more broadly (Yu et al., 2017).
Neurological Research
As noted above, a smaller research thread has explored RAD-140 in neuroprotection models, hypothesizing that androgen receptor activity in neuronal tissue could inform future research into neurodegenerative disease pathways.
Functional Research Insights
Preclinical rodent studies have reported dose-dependent increases in lean tissue mass markers alongside comparatively lower activation of prostate-tissue androgenic markers, which researchers have used to support the tissue-selectivity hypothesis (Miller et al., 2011). However, it is important to note that these findings are derived exclusively from animal models, and no standardized human dosing protocol exists in the peer-reviewed literature.
Separately, case reports in clinical toxicology journals have documented instances of liver injury associated with unsupervised RAD-140 use outside of research settings, underscoring why researchers emphasize that this compound remains investigational and is not established as safe for human consumption in any context (Flores et al., 2020).
Because purity and formulation consistency significantly affect the reliability of research outcomes, laboratories sourcing this compound typically prioritize vendors offering verified third-party testing. Research groups working with RAD-140 for strength and muscle studies often reference suppliers such as BehemothLabz, which provides batch-specific certificates of analysis for its research compounds, a practice that helps reduce variability introduced by inconsistent raw material sourcing.
Broader Scientific Implications
RAD-140’s tissue-selectivity hypothesis has made it a useful model compound for researchers studying how androgen receptor activation might theoretically be decoupled from unwanted androgenic effects, a question with implications extending beyond muscle science into fields such as osteoporosis research, hormone-sensitive oncology, and age-related muscle wasting studies (sarcopenia research). Its non-steroidal structure also continues to inform medicinal chemistry research into next-generation SARMs designed with improved selectivity profiles.
At the same time, the compound’s documented case reports of adverse liver effects in non-research contexts illustrate why investigational compounds like RAD-140 remain confined to laboratory research rather than any human application, and why researchers continue to call for more rigorous long-term toxicology data.
Conclusion
Current research on RAD-140 remains preclinical and investigational. Studies examining its androgen receptor binding affinity, tissue-selectivity hypothesis, and potential relevance to strength and muscle science have contributed meaningfully to the broader SARM research field, but this compound has not progressed through controlled human clinical trials, and it is not approved by the FDA for any human or veterinary use. It remains intended strictly for research purposes only.
As selective androgen receptor modulator research continues to evolve, RAD-140 is likely to remain a reference compound for scientists studying tissue-selective androgen signaling. Continued preclinical investigation, along with more comprehensive toxicological data, will be necessary before any conclusions can be drawn about its broader research relevance.
